| Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule | 10/24 09:15 | globenewswire.com |
| Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium | 10/23 09:15 | globenewswire.com |
| Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium | 10/09 09:15 | globenewswire.com |
| Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study | 09/25 09:15 | globenewswire.com |
| Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference | 09/04 09:15 | globenewswire.com |
| Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter | 09/03 09:15 | globenewswire.com |
| Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now | 09/02 10:55 | zacks.com |
| Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript | 08/14 20:18 | seekingalpha.com |
| Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates | 08/14 18:36 | zacks.com |
| Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results | 08/07 09:15 | globenewswire.com |